Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Red Blood Cell Transfusion Benefits Analyzed for Trauma Patients

By LabMedica International staff writers
Posted on 02 Jul 2014
The risks and benefits of red blood cell transfusions for patients with trauma and major bleeding might vary considerably based on a patient's predicted risk of death on arrival at a trauma center.

Trauma patients who have the highest predicted risk of death on arrival at a trauma center receive the greatest benefit from red blood cell transfusions, but for those with the lowest predicted risk of death at baseline red blood cell transfusion is associated with a higher chance of death.

Scientists at the London School of Hygiene and Tropical Medicine (UK) evaluated the association between receiving red blood cell (RBC) transfusion versus not receiving a RBC transfusion with deaths by all causes at 28 days post-trauma. More...
The findings were stratified by predicted risk of death based on clinical observations on arrival at the trauma center. The investigators included 20,127 trauma patients with significant bleeding from 274 hospitals in 40 countries in their study.

The authors found that those at greatest predicted risk of dying, greater than 50%, had a smaller chance of death from all causes if they were transfused, while for those in the 21% to 50% risk group there was no significant difference in their chance of dying based on whether they are transfused or not. Patients at a 6% to 10% chance of death had a high odd ratio (OR) of 2.31 for dying if they received a transfusion, while for those whose initial risk was below 6%, the OR for death associated with transfusion was very high at 5.40. RBC transfusion was associated with 5.1 more deaths per 100 patients in the patient group with the lowest predicted risk of death but with 11.9 fewer deaths per 100 patients in the group with the highest predicted risk of death.

The authors concluded that although RBC transfusion might be life-saving for patients with hemorrhagic shock, uncertainty remains about the best early transfusion strategy in other patients. Their study suggests that blood transfusion could be harmful for those patients whose predicted risk of death is low. However, as the study was observational, important biases cannot be ruled out, and they do not claim a causal link.

Druin Burch, MD, a consulting editor of the journal, said, “With so many dying each year, and with deaths from injury set to rise in importance as road traffic crashes and violent injuries account for a greater portion of the global burden of disease, we have a compelling reason to improve and rationalize our transfusion strategies.” The study was published on June 17, 2014, in the journal Public Library of Science Medicine.

Related Links:

London School of Hygiene and Tropical Medicine



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.